Inflammatory bowel disease can be caused by the dysfunction of the intestinal mucosal barrier and dysregulation of gut microbiota. Traditional treatments use drugs to manage inflammation with possible probiotic therapy as an adjuvant. However, current standard practices often suffer from metabolic instability, limited targeting and result in unsatisfactory therapeutic outcomes. Here we report on artificial-enzyme-modified Bifidobacterium longum probiotics for reshaping a healthy immune system in inflammatory bowel disease. Probiotics can promote the targeting and retention of the biocompatible artificial enzymes to persistently scavenge elevated reactive oxygen species and alleviate inflammatory factors. The reduced inflammation caused by artificial enzymes improves bacterial viability to rapidly reshape the intestinal barrier functions and restore the gut microbiota. The therapeutic effects are demonstrated in murine and canine models and show superior outcomes to traditional clinical drugs.

炎症性肠病可由肠粘膜屏障功能障碍和肠道微生物群失调引起。传统疗法使用药物来控制炎症，并辅以可能的益生菌疗法。然而，目前的标准做法往往存在代谢不稳定、靶向受限等问题，导致治疗结果不尽如人意。在这里，我们报告了人工酶修饰的长双歧杆菌重塑炎症性肠病健康免疫系统的益生菌。益生菌可以促进生物相容性人工酶的靶向和保留，以持续清除升高的活性氧并减轻炎症因子。人工酶引起的炎症减少可提高细菌活力，从而快速重塑肠道屏障功能并恢复肠道微生物群。治疗效果在小鼠和犬类模型中得到证实，并显示出优于传统临床药物的结果。